<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34991703</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>10</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1745-6215</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Jan</Month><Day>06</Day></PubDate></JournalIssue><Title>Trials</Title><ISOAbbreviation>Trials</ISOAbbreviation></Journal><ArticleTitle>Double-blind placebo-controlled randomized clinical trial to assess the efficacy of montelukast in mild to moderate respiratory symptoms of patients with long COVID: E-SPERANZA COVID Project study protocol.</ArticleTitle><Pagination><StartPage>19</StartPage><MedlinePgn>19</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">19</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13063-021-05951-w</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The coronavirus disease 2019 (COVID-19) pandemic continues to affect the globe. After 18 months of the SARS-CoV-2 emergence, clinicians have clearly defined a subgroup of patients with lasting, disabling symptoms. While big strides have been made in understanding the acute phase of SARS-CoV-2 infection, the pathophysiology of long COVID is still largely unknown, and evidence-based, effective treatments for this condition remain unavailable.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To evaluate the efficacy of 10&#x2009;mg oral montelukast every 24&#x2009;h versus placebo in improving quality of life associated with mild to moderate respiratory symptoms in patients with long COVID as measured with the COPD Assessment Test (CAT) questionnaire. The secondary objectives will evaluate the effect of montelukast versus placebo on improving exercise capacity, COVID-19 symptoms (asthenia, headache, mental confusion or brain fog, ageusia, and anosmia), oxygen desaturation during exertion, functional status, and mortality.</AbstractText><AbstractText Label="METHODS AND ANALYSIS" NlmCategory="METHODS">Phase III, randomized, double-blind clinical trial. We will include 18- to 80-year-old patients with SARS-CoV-2 infection and mild to moderate respiratory symptoms lasting more than 4&#x2009;weeks. Participants will be randomly allocated in a 1:1 ratio to the intervention (experimental treatment with 10&#x2009;mg/day montelukast) or the control group (placebo group), during a 28-day treatment. Follow-up will finish 56&#x2009;days after the start of treatment. The primary outcome will be health-related quality of life associated with respiratory symptoms according to the COPD Assessment Test 4&#x2009;weeks after starting the treatment. The following are the secondary outcomes: (a) exercise capacity and oxygen saturation (1-min sit-to-stand test); (b) Post-COVID-19 Functional Status Scale; (c) other symptoms: asthenia, headache, mental confusion (brain fog), ageusia, and anosmia (Likert scale); (d) use of healthcare resources; (e) mortality; (f) sick leave duration in days; and (g) side effects of montelukast.</AbstractText><AbstractText Label="ETHICS AND DISSEMINATION" NlmCategory="BACKGROUND">This study has been approved by the Clinical Research Ethics Committee of the IDIAPJGol (reference number 21/091-C). The trial results will be published in open access, peer-reviewed journals and explained in webinars to increase awareness and understanding about long COVID among primary health professionals.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">ClinicalTrials.gov NCT04695704 . Registered on January 5, 2021. EudraCT number 2021-000605-24. Prospectively registered.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mera-Cordero</LastName><ForeName>Francisco</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-6599-0506</Identifier><AffiliationInfo><Affiliation>Primary Care EAP El Pla Sant Feliu de Llobregat, Primary Care Management Costa de Ponent, Catalan Institute of Health, L'Hospitalet de Llobregat, Spain. fmera@ambitcp.catsalut.net.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institut Universitari de Recerca en Atenci&#xf3; Prim&#xe0;ria Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain. fmera@ambitcp.catsalut.net.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bonet-Monne</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institut Universitari de Recerca en Atenci&#xf3; Prim&#xe0;ria Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pharmacy Unit SAP Baix Llobregat Centre, Primary Care Management Costa Ponent, Catalan Institute of Health, Cornell&#xe0; de Llobregat, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Almeda-Ortega</LastName><ForeName>Jes&#xfa;s</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institut Universitari de Recerca en Atenci&#xf3; Prim&#xe0;ria Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Primary Care Research Support Unit (USR) Costa de Ponent, Primary Care Management Costa de Ponent, Catalan Institute of Health, Cornell&#xe0; de Llobregat, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garc&#xed;a-Sangen&#xed;s</LastName><ForeName>Ana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institut Universitari de Recerca en Atenci&#xf3; Prim&#xe0;ria Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Trials Research Unit (UICEC) IDIAPJGol - Platform SCReN, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cunillera-Pu&#xe8;rtolas</LastName><ForeName>Oriol</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Primary Care Research Support Unit (USR) Costa Ponent, Institut Universitari de Recerca en Atenci&#xf3; Prim&#xe0;ria Jordi Gol i Gurina (IDIAPJGol), Cornell&#xe0; de Llobregat, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Contreras-Martos</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institut Universitari de Recerca en Atenci&#xf3; Prim&#xe0;ria Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Primary Care Research Support Unit (USR) Costa de Ponent, Primary Care Management Costa de Ponent, Catalan Institute of Health, Cornell&#xe0; de Llobregat, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alvarez-Mu&#xf1;oz</LastName><ForeName>Gemma</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Institut Universitari de Recerca en Atenci&#xf3; Prim&#xe0;ria Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Primary Care Covid Notification and Monitoring Unit UNSC Metropolitana SUD, Primary Care Management Costa de Ponent, Catalan Institute of Health, L'Hospitalet de Llobregat, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Monf&#xe0;</LastName><ForeName>Ramon</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Institut Universitari de Recerca en Atenci&#xf3; Prim&#xe0;ria Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Trials Research Unit (UICEC) IDIAPJGol - Platform SCReN, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Balanzo-Jou&#xe9;</LastName><ForeName>Marina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institut Universitari de Recerca en Atenci&#xf3; Prim&#xe0;ria Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pharmacy Unit SAP Baix Llobregat Centre, Primary Care Management Costa Ponent, Catalan Institute of Health, Cornell&#xe0; de Llobregat, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morros</LastName><ForeName>Rosa</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Institut Universitari de Recerca en Atenci&#xf3; Prim&#xe0;ria Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Trials Research Unit (UICEC) IDIAPJGol - Platform SCReN, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacology and Therapeutics, Universitat Aut&#xf2;noma de Barcelona, Bellaterra, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salvador-Gonzalez</LastName><ForeName>Betlem</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Institut Universitari de Recerca en Atenci&#xf3; Prim&#xe0;ria Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Primary Care Research Support Unit (USR) Costa de Ponent, Primary Care Management Costa de Ponent, Catalan Institute of Health, Cornell&#xe0; de Llobregat, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Trials Research Unit (UICEC) IDIAPJGol - Platform SCReN, Barcelona, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT04695704</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D000078325">Clinical Trial Protocol</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>01</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Trials</MedlineTA><NlmUniqueID>101263253</NlmUniqueID><ISSNLinking>1745-6215</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000085">Acetates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003521">Cyclopropanes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011804">Quinolines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013440">Sulfides</NameOfSubstance></Chemical><Chemical><RegistryNumber>MHM278SD3E</RegistryNumber><NameOfSubstance UI="C093875">montelukast</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Trials. 2022 Feb 9;23(1):130. doi: 10.1186/s13063-022-06073-7</RefSource><PMID Version="1">35139906</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000085" MajorTopicYN="N">Acetates</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003521" MajorTopicYN="N">Cyclopropanes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000089382" MajorTopicYN="N">Oxygen Saturation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011804" MajorTopicYN="N">Quinolines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013440" MajorTopicYN="N">Sulfides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Dyspnea</Keyword><Keyword MajorTopicYN="N">Health status</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">Montelukast</Keyword><Keyword MajorTopicYN="N">Primary care</Keyword><Keyword MajorTopicYN="N">Quality of life</Keyword><Keyword MajorTopicYN="N">Randomized controlled trial</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>9</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>12</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>1</Month><Day>7</Day><Hour>5</Hour><Minute>48</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>1</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>1</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34991703</ArticleId><ArticleId IdType="pmc">PMC8733792</ArticleId><ArticleId IdType="doi">10.1186/s13063-021-05951-w</ArticleId><ArticleId IdType="pii">10.1186/s13063-021-05951-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Informe n&#xb0; 85. Situaci&#xf3;n de COVID-19 en Espa&#xf1;a. Informe COVID-19. 30 de junio de 2021. Equipo COVID-19. RENAVE. CNE. CNM (Instituto de Salud Carlos III).</Citation></Reference><Reference><Citation>Lechien JR, Chiesa-Estomba CM, Place S, Van Laethem Y, Cabaraux P, Mat Q. et al; COVID-19 Task Force of YO IFOS. Clinical and epidemiological characteristics of 1420 European patients with mild-to-moderate coronavirus disease 2019. J Intern Med. 2020;288(3):335&#x2013;344. doi: 10.1111/joim.13089.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/joim.13089</ArticleId><ArticleId IdType="pmc">PMC7267446</ArticleId><ArticleId IdType="pubmed">32352202</ArticleId></ArticleIdList></Reference><Reference><Citation>Carf&#xec; A, Bernabei R, Landi F. Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent symptoms in patients after acute COVID-19. JAMA. 2020;324(6):603&#x2013;605. doi: 10.1001/jama.2020.12603.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12603</ArticleId><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>Navabi N. Long COVID: how to define it and how to manage it. BMJ webinar. BMJ. 2020;370:m3489. doi: 10.1136/bmj.m3489.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m3489</ArticleId><ArticleId IdType="pubmed">32895219</ArticleId></ArticleIdList></Reference><Reference><Citation>Yelin D, Wirtheim E, Vetter P, Kalil AC, Bruchfeld J, Runold M, Guaraldi G, Mussini C, Gudiol C, Pujol M, Bandera A, Scudeller L, Paul M, Kaiser L, Leibovici L. Long term consequences of COVID-19: research needs. Lancet Infect Dis. 2020;20(10):1115&#x2013;1117. doi: 10.1016/S1473-3099(20)30701-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(20)30701-5</ArticleId><ArticleId IdType="pmc">PMC7462626</ArticleId><ArticleId IdType="pubmed">32888409</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID-19 rapid guideline: managing the long-term effects of COVID-19. NICE guideline [NG188] www.nice.org.uk/guidance/ng188. National Institute for Health and Care Excellence, Royal College of General Practitioners, HealthcareImprovementScotland/SIGN. Published date: 18 December 2020</Citation></Reference><Reference><Citation>Editorial. Meeting the challenge of long COVID. Nat Med. 2020 Dec;26(12):1803.</Citation><ArticleIdList><ArticleId IdType="pubmed">33288947</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID symptom study. How long does COVID last? June 6, 2020. https://covid19.joinzoe.com/post/covid long-term</Citation></Reference><Reference><Citation>Davis HR, Assaf GS, McCorkell L, Wei H, Low RJ, Re&#x2019;em Y, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021;15:101019. doi: 10.1016/j.eclinm.2021.101019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.101019</ArticleId><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostrosky T, Perelman C, Sepulveda R, Rebolledo P, Cuapio A, et al. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. medRxiv [Preprint] 2021;30:2021.01.27.21250617.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8352980</ArticleId><ArticleId IdType="pubmed">34373540</ArticleId></ArticleIdList></Reference><Reference><Citation>Michelen M, Manoharan L, Elkheir N, Cheng V, Dagens D, Hastie C, et al. Characterising long-term COVID-19: a rapid living systematic review. medRxiv [Preprint] 2020.12.08.20246025.</Citation></Reference><Reference><Citation>Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020;46(4):586&#x2013;590. doi: 10.1007/s00134-020-05985-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-020-05985-9</ArticleId><ArticleId IdType="pmc">PMC7079879</ArticleId><ArticleId IdType="pubmed">32125455</ArticleId></ArticleIdList></Reference><Reference><Citation>Song P, Li W, Xie J, Hou Y, You C. Cytokine storm induced by SARS-CoV-2. Clin Chim Acta. 2020;509:280&#x2013;287. doi: 10.1016/j.cca.2020.06.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cca.2020.06.017</ArticleId><ArticleId IdType="pmc">PMC7283076</ArticleId><ArticleId IdType="pubmed">32531256</ArticleId></ArticleIdList></Reference><Reference><Citation>Gazzaruso C, Carlo Stella N, Mariani G, Nai C, Coppola A, Naldani D, Gallotti P. High prevalence of antinuclear antibodies and lupus anticoagulant in patients hospitalized for SARS-CoV-2 pneumonia. Clin Rheumatol. 2020;39(7):2095&#x2013;2097. doi: 10.1007/s10067-020-05180-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-020-05180-7</ArticleId><ArticleId IdType="pmc">PMC7251560</ArticleId><ArticleId IdType="pubmed">32462425</ArticleId></ArticleIdList></Reference><Reference><Citation>Das UN. Can bioactive lipids inactivate coronavirus (COVID-19)? Arch Med Res. 2020;51(3):282&#x2013;286. doi: 10.1016/j.arcmed.2020.03.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arcmed.2020.03.004</ArticleId><ArticleId IdType="pmc">PMC7270578</ArticleId><ArticleId IdType="pubmed">32229155</ArticleId></ArticleIdList></Reference><Reference><Citation>Costela-Ruiz VJ, Illescas-Montes R, Puerta-Puerta JM, Ruiz C, Melguizo-Rodr&#xed;guez L. SARS-CoV-2 infection: the role of cytokines in COVID-19 disease. Cytokine Growth Factor Rev. 2020;54:62&#x2013;75. doi: 10.1016/j.cytogfr.2020.06.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cytogfr.2020.06.001</ArticleId><ArticleId IdType="pmc">PMC7265853</ArticleId><ArticleId IdType="pubmed">32513566</ArticleId></ArticleIdList></Reference><Reference><Citation>Pedersen SF, Ho YC. SARS-CoV-2: a storm is raging. J Clin Invest. 2020;130(5):2202&#x2013;2205. doi: 10.1172/JCI137647.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI137647</ArticleId><ArticleId IdType="pmc">PMC7190904</ArticleId><ArticleId IdType="pubmed">32217834</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamada T, Ichinose M. Leukotriene receptor antagonists and antiallergy drugs. Handb Exp Pharmacol. 2017;237:153&#x2013;169. doi: 10.1007/164_2016_72.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/164_2016_72</ArticleId><ArticleId IdType="pubmed">27826703</ArticleId></ArticleIdList></Reference><Reference><Citation>Copertino DC, Duarte RRR, Powell TR, Rougvie MM, Nixon DF. Montelukast drug activity and potential against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) J Med Virol. 2021;93(12):187&#x2013;189. doi: 10.1002/jmv.26299.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26299</ArticleId><ArticleId IdType="pmc">PMC7405283</ArticleId><ArticleId IdType="pubmed">32658304</ArticleId></ArticleIdList></Reference><Reference><Citation>Davino-Chiovatto JE, Oliveira-Junior MC, MacKenzie B, Santos-Dias A, Almeida-Oliveira AR, Aquino-Junior JCJ, Brito AA, Rigonato-Oliveira NC, Damaceno-Rodrigues NR, Oliveira APL, Silva AP, Consolim-Colombo FM, Aimbire F, Castro-Faria-Neto HC, Vieira RP. Montelukast, leukotriene inhibitor, reduces LPS-induced acute lung inflammation and human neutrophil activation. Arch Bronconeumol (Engl Ed). 2019;55(11):573&#x2013;580. doi: 10.1016/j.arbres.2019.05.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arbres.2019.05.003</ArticleId><ArticleId IdType="pubmed">31257011</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhattacharyya D. Reposition of montelukast either alone or in combination with levocetirizine against SARS-CoV-2. Med Hypotheses. 2020;144:110046. doi: 10.1016/j.mehy.2020.110046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mehy.2020.110046</ArticleId><ArticleId IdType="pmc">PMC7321662</ArticleId><ArticleId IdType="pubmed">33254480</ArticleId></ArticleIdList></Reference><Reference><Citation>Barr&#xe9; J, Sabatier JM, Annweiler C. Montelukast drug may improve COVID-19 prognosis: a review of evidence. Front Pharmacol. 2020;11:1344. doi: 10.3389/fphar.2020.01344.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2020.01344</ArticleId><ArticleId IdType="pmc">PMC7500361</ArticleId><ArticleId IdType="pubmed">33013375</ArticleId></ArticleIdList></Reference><Reference><Citation>Fidan C, Aydo&#x11f;du A. As a potential treatment of COVID-19: montelukast. Med Hypotheses. 2020;142:109828. doi: 10.1016/j.mehy.2020.109828.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mehy.2020.109828</ArticleId><ArticleId IdType="pmc">PMC7211747</ArticleId><ArticleId IdType="pubmed">32416408</ArticleId></ArticleIdList></Reference><Reference><Citation>Almerie MQ, Kerrigan DD. The association between obesity and poor outcome after COVID-19 indicates a potential therapeutic role for montelukast. Med Hypotheses. 2020;143:109883. doi: 10.1016/j.mehy.2020.109883.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mehy.2020.109883</ArticleId><ArticleId IdType="pmc">PMC7255216</ArticleId><ArticleId IdType="pubmed">32492562</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan AR, Misdary C, Yegya-Raman N, Kim S, Narayanan N, Siddiqui S, et al. Montelukast in hospitalized patients diagnosed with COVID-19. J Asthma. 2021:1&#x2013;7. 10.1080/02770903.2021.1881967.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7938648</ArticleId><ArticleId IdType="pubmed">33577360</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilchesky M, Tranmer G, Grad R. The COVID-19 Symptom Montelukast Trial (COSMO). ClinicalTrials.gov Identifier: NCT04389411. Fecha de consulta [12.02.2021]. Disponible en: https://clinicaltrials.gov/ct2/show/NCT04389411</Citation></Reference><Reference><Citation>Investigation of the effect of montelukast in COVID-19. A national, multi-center, open-label, three-arm, phase II study to investigate the effect of montelukast between emergency room visits and hospitalizations in COVID-19 pneumonia in comparison with standard treatment. Fecha de consulta [12.02.2021]. Disponible en: https://clinicaltrials.gov/ct2/show/NCT04718285?cond=COVID19&amp;intr=&#x201c;Montelukast&#x201d;&amp;draw=2&amp;rank=2</Citation></Reference><Reference><Citation>Mera Cordero F, Salvador Gonz&#xe1;lez B, Morros R, Bonet Monne S, Cos FX, Almeda OJ. Effectiveness of montelukast against exuberant immune activation in &#x201c;long COVID&#x201d;. Biomed J Sci &amp; Tech Res. 2021;33(2):25750&#x2013;25751. doi: 10.26717/BJSTR.2021.33.005385.</Citation><ArticleIdList><ArticleId IdType="doi">10.26717/BJSTR.2021.33.005385</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Leidy NK. Development and first validation of the COPD Assessment Test. Eur Resp J. 2009;34(3):648&#x2013;654. doi: 10.1183/09031936.00102509.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/09031936.00102509</ArticleId><ArticleId IdType="pubmed">19720809</ArticleId></ArticleIdList></Reference><Reference><Citation>Kon SS, Canavan JL, Jones SE, Nolan CM, Clark AL, Dickson MJ, et al. Minimum clinically important difference for the COPD Assessment Test: a prospective analysis. Lancet Respir Med. 2014;2(3):195&#x2013;203. doi: 10.1016/S2213-2600(14)70001-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(14)70001-3</ArticleId><ArticleId IdType="pubmed">24621681</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenhalgh T, Javid B, Knight M, Inada-Kim M. What is the efficacy and safety of rapid exercise test for exertional desaturation in COVID-19? https://www.cebm.net/covid-19/what-is-the-efficacy-and-safety-of-rapid-exercise-tests-for-exertional-desaturation-in-covid-19/</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7961172</ArticleId><ArticleId IdType="pubmed">33726854</ArticleId></ArticleIdList></Reference><Reference><Citation>Klok FA, Boon GKAM, Barco S, Endres M, Geelhoed JJM, Knauss S, et al. The Post-COVID-19 Functional Status Scale: a tool to measure functional status over time after COVID-19. Eur Respir J. 2020;56(1):2001494. doi: 10.1183/13993003.01494-2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.01494-2020</ArticleId><ArticleId IdType="pmc">PMC7236834</ArticleId><ArticleId IdType="pubmed">32398306</ArticleId></ArticleIdList></Reference><Reference><Citation>Ca&#xf1;adas I, S&#xe1;nchez-Bruno A. Categor&#xed;as de respuesta en escalas tipo Likert. Psicothema. 1998;10(3):623&#x2013;631.</Citation></Reference><Reference><Citation>Wang J, Guo S, Zeng M, Yu P, Mo W. Observation of the curative effect of device-guided rehabilitation on respiratory function in stable patients with chronic obstructive pulmonary disease. Medicine. 2019;98(8):e14034. doi: 10.1097/MD.0000000000014034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000014034</ArticleId><ArticleId IdType="pmc">PMC6408035</ArticleId><ArticleId IdType="pubmed">30813125</ArticleId></ArticleIdList></Reference><Reference><Citation>Fletcher CM, Elmes PC, Fairbairn MB, Wood CH. The significance of respiratory symptoms and the diagnosis of chronic bronchitis in a working population. Br Med J. 1959;2(5147):257&#x2013;266. doi: 10.1136/bmj.2.5147.257.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.2.5147.257</ArticleId><ArticleId IdType="pmc">PMC1990153</ArticleId><ArticleId IdType="pubmed">13823475</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap) &#x2013; a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377&#x2013;381. doi: 10.1016/j.jbi.2008.08.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2008.08.010</ArticleId><ArticleId IdType="pmc">PMC2700030</ArticleId><ArticleId IdType="pubmed">18929686</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O&#x2019;Neal L, et al. REDCap Consortium. The REDCap Consortium: building an international community of software platform partners. J Biomed Inform. 2019;95:103208. doi: 10.1016/j.jbi.2019.103208.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2019.103208</ArticleId><ArticleId IdType="pmc">PMC7254481</ArticleId><ArticleId IdType="pubmed">31078660</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>